Washington State Responds To Attorney General Sessions’ Veiled Threats

Jeff_Sessions_(29299022521)As first reported by Tom Angell of MassRoots.com, Washington State Governor Jay Inslee and Attorney General Bob Ferguson responded to a July 24 letter from US Attorney General Jeff Sessions, in which Sessions’ made multiple allegations all based on a single misleading 2016 report.

One would say, they didn’t pull any punches:

“Your letter, citing the March 2016 Northwest High Intensity Drug Trafficking Area (NW HIDTA) report on marijuana in Washington, makes a number of allegations that are outdated, incorrect, or based on incomplete information.”

 

Cutting right to the heart of the matter, i.e. facts, the Washington state leaders again articulated their desire to educate the (seemingly willing) ignorant Sessions.

“We have twice requested an in-person meeting with you because we believe it will lead to better understanding than exchanging letters. If we can engage in a more direct dialogue, we might avoid this sort of miscommunication and make progress on the issues that are important to both of us. We therefore reiterate our request to meet with you, followed by further appropriate meetings between state and DOJ officials.”

 

One of the most basic functions of government is to simply provide consistency and certainty in law enforcement. So after repeated efforts by the state’s leadership to receive clarification, basic facets of the Department of Justice’s approach are still unknown. In yet another attempt for guidance, the Governor and state Attorney General requested information on:

  • Whether DOJ intends to follow recommendations from its Task Force on Crime Reduction and Public Safety—in particular, its reported recommendation to continue previous federal policy on state legalization of marijuana.
  • Whether President Trump’s previous statements of support for medical marijuana, and leaving recreational marijuana legalization to the states, represent the policy of the federal government.
  • Whether DOJ will support reasonable federal policies allowing financial institutions to provide service to licensed marijuana businesses, in order to avoid the public safety risks and transparency problems associated with all-cash businesses.
  • How state-regulated marijuana should be treated by the federal government following the President’s declaration that the opioid crisis constitutes a national emergency, and whether the federal government will support objective, independent research into the effects of marijuana law reform on opioid use and abuse.
  • Whether the federal government will help protect public health by supporting agricultural research on the safety of pesticides used in marijuana cultivation.
  • Whether the federal government will support research into expedited roadside DUI testing methods for law enforcement, as alternatives to blood draws.

 

How Attorney General Sessions will respond, only time will tell.

You can click HERE to send a message to your Representative to urge their support for The Respect State Marijuana Laws Act, bipartisan legislation to prevent the Department of Justice from enforcing federal prohibition in states that have chosen to legalize medical or adult-use marijuana.

You can view the full letter from Governor Inslee and AG Ferguson below:

Washington Officials Respond to Sessions Marijuana Letter by tomangell on Scribd

The Marijuana Justice Act Introduced In Senate

Senator Cory Booker (D-NJ)

Senator Cory Booker (D-NJ)

Senator Corey Booker (D-NJ) has introduced comprehensive marijuana reform legislation, the Marijuana Justice Act of 2017.

The bill would (1) remove marijuana from the US Controlled Substances Act, thereby ending the federal criminalization of cannabis; (2) incentivize states to mitigate existing and ongoing racial disparities in state-level marijuana arrests; (3) expunge federal convictions specific to marijuana possession; (4) allow individuals currently serving time in federal prison for marijuana-related violations to petition the court for resentencing; (5) and create a community reinvestment fund to invest in communities most impacted by the failed War on Drugs.

Click here to watch the video of Senator Booker discussing the bill.

“Not only is it imperative we end our failed experiment of marijuana prohibition, we must also ensure justice for those who suffered most under these draconian policies,” said NORML Executive Director Erik Altieri, “We applaud Senator Booker for introducing this robust legislation that would not only remove marijuana from the Controlled Substances Act, but provide a path forward for the individuals and communities that were most disproportionately targeted by our nation’s failed war on marijuana consumers.”

Thirty states, Washington, DC and the US territories of Guam and Puerto Rico have enacted legislation specific to the physician-authorized use of cannabis, while an estimated 63 million Americans now reside in jurisdictions where anyone over the age of 21 may possess cannabis legally. Voters overwhelmingly support these policy changes. According to a 2017 Quinnipiac University poll, 59 percent of Americans support full marijuana legalization and 71 percent believe that states, not the federal government, should set marijuana policy.

To date, these statewide regulatory programs are operating largely as voters and politicians intended. The enactment of these policies have not negatively impacted workplace safetycrime ratestraffic safety, or youth use patterns. They have stimulated economic development and created hundreds of millions of dollars in new tax revenue. Specifically, a 2017 report estimates that 123,000 Americans are now working full-time in the cannabis industry. Tax revenues from states like Colorado, Oregon, and Washington now exceed initial projections. Further, numerous studies have identified an association between cannabis access and lower rates of opioid useabusehospitalizations, and mortality.

017

 

Vote Expected Tomorrow On Medical Marijuana

Medical marijuanaTomorrow, the Senate Appropriations Committee will have to decide: Will they protect our nation’s 2 million lawful medical marijuana patients or subject them to the wrath of Attorney General Jeff Sessions?

The amendment they will be debating, known as Rohrabacher-Blumenauer, simply prevents the United States Department of Justice from spending any of our tax dollars enforcing federal marijuana prohibition against the 30 states which have now, or are in the process of, implementing a medical cannabis system.

Tell your Senators to protect patients by supporting the Rohrabacher-Blumenauer Amendment

There is NO moral reason to punish qualified patients and veterans from accessing marijuana for its therapeutic effects. Recently released data has revealed that the enactment of medical cannabis access is associated with lower rates of opioid abuse and mortality, and does not negatively impact workplace safety, teen use rates, or motor vehicle safety.

Yet, in a letter to members of Congress on May 1, Sessions demanded the end of Rohrabacher-Blumenauer, citing: “The Department must be in a position to use all laws available to combat the transnational drug organizations and dangerous drug traffickers who threaten American lives.”

This is the delusional leadership we have coming out of the Justice Department. A man who equates those suffering from PTSD, cancer, AIDS, and other dire medical conditions to members of violent drug cartels.

We cannot allow Jeff Sessions to be the only one communicating with Congress. SEND A MESSAGE TO YOUR SENATORS NOW.

Study: Adult Use Marijuana Laws Do Not Adversely Impact Traffic Fatality Rates

thumbs_upThe enactment of statewide laws regulating the adult use and sale of cannabis is not associated with subsequent changes in traffic fatality rates, according to an analysis of traffic safety data (“Crash fatality rates after recreational marijuana legalization in Washington and Colorado”) published today in the American Journal of Public Health.

Investigators from the University of Texas-Austin evaluated crash fatality rates in Colorado and Washington pre- and post-legalization. They compared these rates to those of eight control states that had not enacted any significant changes in their marijuana laws.

“We found no significant association between recreational marijuana legalization in Washington and Colorado and subsequent changes in motor vehicle fatality rates in the first three years after recreational marijuana legalization,” author concluded.

They further reported, “[W]e also found no association between recreational marijuana legalization and total crash rates when analyzing available state-reported nonfatal crash statistics.”

Commenting on the findings, NORML Deputy Director Paul Armentano said: “These conclusions ought to be reassuring to lawmakers and those in the public who have concerns that regulating adult marijuana use may inadvertently jeopardize public safety. These results indicate that such fears have not come to fruition, and that such concerns ought not to unduly influence legislators or voters in other jurisdictions that are considering legalizing cannabis.”

A prior study published last year by the same journal reported that the enactment of medical marijuana legalization laws is associated with a reduction in traffic fatalities compared to other states, particularly among younger drivers.

Fatal accident rates have fallen significantly over the past two decades — during the same time that a majority of US states have legalized marijuana for either medical or social use. In 1996, the US National Highway Traffic Safety Administration reported that there were an estimated 37,500 fatal car crashes on US roadways. This total fell to under 30,000 by 2014.

A summary of the study appears online under ‘First Look’ on the apha.org website here.

Mixing booze, pot is a serious threat to traffic safety

Use of marijuana in combination with alcohol by drivers is especially dangerous, according to a study. Drivers who used alcohol, marijuana, or both were significantly more likely to be responsible for causing fatal two-vehicle crashes compared to drivers who were involved in the same crashes but used neither of the substances.

Review Identifies 140 Controlled Clinical Trials Related to Cannabis

Marijuana researchScientists have conducted over 140 controlled clinical trials since 1975 assessing the safety and efficacy of whole-plant cannabis or specific cannabinoids, according to a new literature review published in the journal Critical Reviews in Plant Sciences.

A pair of German researchers identified 140 clinical trials involving an estimated 8,000 participants. Of these, the largest body of literature focused on the use of cannabis or cannabinoids in the treatment of chronic or neuropathic pain. Authors identified 35 controlled studies, involving 2,046 subjects, assessing the use of marijuana or cannabinoids in pain management. In January, the National Academy of Sciences acknowledged that “conclusive or substantial evidence” exists for cannabis’ efficacy in patients suffering from chronic pain.

Cannabinoids have also been well studied as anti-emetic agents and as appetite stimulants. Researchers identified 43 trials evaluating marijuana or its components for these purposes, involving total 2,498 patients. They also identified an additional 14 trials examining the role of cannabis or cannabis-derived extracts in the treatment of multiple sclerosis.

Researchers also identified several additional trials evaluating the use of cannabis or cannabinoids for Crohn’s disease, Tourette’s syndrome, Parkinson’s disease, glaucoma, epilepsy, and various other indications.

A 2014 study published in the Journal of the American Medical Association reported that new drugs typically gain FDA approval on the basis of one or two pivotal clinical trials.

Full text of the study, “Medicinal uses of marijuana and cannabinoids,” appears online here.

Study: Inhaled Cannabis Controls Tics In Patients With Tourette’s Syndrome

Medical marijuanaInhaled cannabis is effective and well-tolerated in patients with Tourette’s Syndrome, according to clinical data published online ahead of print in the Journal of Neuropsychiatry and Clinical Neuroscience.

A team of researchers at the University of Toronto retrospectively assessed the safety and efficacy of inhaled cannabis in 19 TS patients.

Researchers reported, “All study participants experienced clinically significant symptom relief,” including including reductions in obsessive-compulsive symptoms, impulsivity, anxiety, irritability, and rage outbursts. Eighteen of 19 patients experienced decreased tic severity. Cannabis was “generally well tolerated” by study subjects.

They concluded: “Overall, these study participants experienced substantial improvements in their symptoms. This is particularly striking given that almost all participants had failed at least one anti-tic medication trial. … In conclusion, cannabis seems to be a promising treatment option for tics and associated symptoms.”

Placebo controlled data has previously determined that oral THC dosing also improves tics and obsessive-compulsive behavior in TS patients. However, patients utilizing inhaled cannabis have generally shown greater overall improvement.

An abstract of the study, “Preliminary evidence on cannabis effectiveness and tolerability for adults with Tourette Syndrome,” is online here.

Impactful and Heartfelt Hearing Creates Historic Support for Texas Medical Cannabis Bill

By Jax Finkel
Executive Director, Texas NORML

Late in the evening on Tuesday, May 2nd, the House Public Health Committee held a hearing for HB 2107 which would make the Compassionate Use Program more inclusive for patients with debilitating medical conditions. Many patients stayed late into the evening to provide powerful and emotional testimony. After a powerful hearing with targeted testimony, the authors for the bill jumped from 5 to 75! This is historic and unprecedented in Texas.

TX resident? Please participate in this action to encourage Chairman Price to hold a vote on HB 2107!

Veterans demanded access for service related disabilities. Doctors spoke to the efficacy and safety profile of cannabis. 66 testimonies were offered in support. 187 registered in support. There was only one verbal opposition. It is TBD if there were more registered against not testifying as the full witness list has not been released yet.

Continue to support Texas NORML’s work at the Capitol!

 We are very happy to see that our coordination with the authors and committee members has paid of so well. We appreciated all the speakers that were invited to speak and came to share their story. Thank you to the authors, committee members, staffers, our team and coalition and to all who advocate!

Watch the hearing, which starts at 2:33:44.

Watch Kara’s story which inspired Rep Lucio III to carry the bill.

Please support the important work we are doing in Texas by becoming a sustaining donormaking a donation or becoming a Texas NORML member.

Marijuana Treated Like Alcohol? Legislation Filed In Senate and House

Legalize marijuanaSenator Ron Wyden and Representatives Earl Blumenauer and Jared Polis have introduced legislation in the House and Senate — The Marijuana Revenue and Regulation Act — to permit states to establish their own marijuana regulatory policies free from federal interference. In addition to removing marijuana from the United States Controlled Substances Act, this legislation also removes enforcement power from the US Drug Enforcement Administration in matter concerning marijuana possession, production, and sales — thus permitting state governments to regulate these activities as they see fit.

Email your members of Congress now and urge them to support this effort.

“The first time introduction of this particular piece of legislation in the US Senate is another sign that the growing public support for ending our failed war on cannabis consumers nationwide is continuing to translate into political support amongst federal officials,” said NORML Executive Director Erik Altieri, “With marijuana legalization being supported by 60% of all Americans while Congress’ approval rating is in the low teens, ending our country’s disastrous prohibition against marijuana would not just be good policy, but good politics.”

Twenty-nine states and the District of Columbia have legalized marijuana for qualified patients, while eight states now regulate the production and sale of marijuana to all adults. An estimated 63 million Americans now reside in jurisdictions where anyone over the age of 21 may possess cannabis legally. Voters support these policy changes. According to a 2017 Quinnipiac University poll, 59 percent of Americans support full marijuana legalization and 71 percent believe that states, not the federal government, should set marijuana policy

“If we are truly going to move our nation towards sensible marijuana policies, the removal of marijuana from the Controlled Substances Act is paramount. Annually, 600,000 Americans are arrested for nothing more than the possession of small amounts of marijuana and now is the time for Congress to once and for all end put an end to the national embarrassment that is cannabis prohibition,” said Justin Strekal, NORML Political Director. “Passing this legislation would end the current conflict between state and federal laws and allow the states to implement more sensible and humane marijuana policies, free from the threat of federal incursion.”

These statewide regulatory schemes are operating largely as voters and politicians intended. The enactment of these policies have not negatively impacted workplace safety, crime rates, traffic safety, or youth use patterns. They have stimulated economic development and tax revenue. Specifically, a 2017 report estimates that 123,000 Americans are now working full-time in the cannabis industry. Tax revenues from states like Colorado, Oregon, and Washington now exceed initial projections. Further, numerous studies have identified an association between cannabis access and lower rates of opioid use, abuse, hospitalizations, and mortality.

Senator Ron Wyden (D-OR)

Senator Ron Wyden (D-OR)

“The federal government must respect the decision Oregonians made at the polls and allow law-abiding marijuana businesses to go to the bank just like any other legal business.” Senator Ron Wyden said. “This three-step approach will spur job growth and boost our economy all while ensuring the industry is being held to a fair standard.”

Congressman Jared Polis (D-CO)

Congressman Jared Polis (D-CO)

“Colorado has proven that allowing responsible adults to legally purchase marijuana, gives money to classrooms, not cartels; creates jobs, not addicts; and boosts our economy, not our prison population,” Representative Jared Polis said. “Now, more than ever, it is time we end the federal prohibition on marijuana and remove barriers for states’ that have chosen to legalize marijuana.  This budding industry can’t afford to be stifled by the Trump administration and its mixed-messages about marijuana.  The cannabis industry, states’, and citizens deserve leadership when it comes to marijuana.”

Congressman Earl Blumenauer (D-OR)

Congressman Earl Blumenauer (D-OR)

“As more states follow Oregon’s leadership in legalizing and regulating marijuana, too many people are trapped between federal and state laws,” Representative Earl Blumenauer said. “It’s not right, and it’s not fair. We need change now – and this bill is the way to do it.”

The ongoing enforcement of cannabis prohibition financially burdens taxpayers, encroaches upon civil liberties, engenders disrespect for the law, impedes legitimate scientific research into the plant’s medicinal properties, and disproportionately impacts communities of color.

By contrast, regulating the adult use of marijuana stimulates economic growth, saves lives, and has the support of the majority of the majority of Americans. 

Send a message to your members of Congress urging them to support the Marijuana Revenue and Regulation Act

Weekly Legislative Roundup, 1/28/2017

blogstickerWelcome to this week’s edition of the legislative roundup. With prohibitionists fighting nationwide, from Massachusetts to deny the will of the voters with the implementation of legalization to Hawaii where the state is seeking to impose increased monitoring of drivers who may be under the influence of marijuana, NORML is constantly working to fight the rising tide of anti-science legislation cropping up.

On the proactive “Team Rationality” side, NORML chapters are advancing efforts from reducing criminal penalties in Virginia to expanding worker protections for cannabis consumers in Washington state.

Below are the priority bills that we’ve tracked this week, with more being posted on our http://norml.org/act page every day.

If you have not yet, make sure to sign up for our email list and we will keep you posted as these bills and more move through your home state legislature and at the federal level.

Thanks for all you do,

Justin

 

Arkansas

Legislative efforts are pending to amend the state’s voter-initiated medical marijuana law in a manner that would restrict qualified patients from smoking herbal preparations of the plant. Republican Gov. Asa Hutchinson indicates that he favors the plan.

NORML opposes this effort to fundamentally change the law for the following reasons.

The inhalation of herbal cannabis is associated with the rapid onset of drug effect while the oral consumption of other preparations, such as oils, extracts, or pills, is associated with significantly delayed onset. For patients seeking rapid relief from symptoms, such as those suffering from severe nausea, seizures, or spasms, inhaling herbal cannabis is the fastest and most effective route of administration. Inhaling cannabis also permits patients to better regulate their dose.

Further, the effects of orally ingested cannabis are far less predictable in comparison to inhaled cannabis. This is because there exists far greater variability in the ways that marijuana is metabolized when it is consumed orally — meaning that patients may experience disparate and even dysphoric effects from dose to dose, even in instances where the dose is standardized.

AR Resident? Click here to email your representatives to oppose this effort.

Additionally, SB 130 prohibits individuals from operating a motor vehicle if they have 5 or more nanograms of THC per milliliter in their blood. NORML opposes  this proposal.

It should not be presumed that the detection of THC is predictive of psychomotor impairment and such a presumption should not be codified in Arkansas traffic safety statutes. The imposition and enforcement of this measure risks inappropriately convicting unimpaired subjects of traffic safety violations.

AR Resident? Click here to email your representatives to oppose this effort.

Hawaii

Legislation is pending, SB 548, to legalize the possession and use of limited amounts of marijuana for those over the age of 21.

According to 2014 statewide poll, 66 percent of Hawaii voters support the taxation and regulation of marijuana.

HI Resident? Click here to email your representatives to urge them to support this effort.

Additionally, Legislation is pending, SB 17, that seeks to establish a per se limit of “five nanograms or more per milliliter of active tetrahydrocannabinol” for anyone driving a motor vehicle.

NORML opposes this proposal.

It should not be presumed that the detection of THC is predictive of psychomotor impairment and such a presumption should not be codified in Hawaii traffic safety statutes. The imposition and enforcement of this measure risks inappropriately convicting unimpaired subjects of traffic safety violations.

HI Resident? Click here to email your representatives to urge them to support this effort.

Massachusetts

On Wednesday, December 28, a handful of lawmakers met in a special session and voted to delay the roll out of retail marijuana providers from January 1, 2018 to July 1, 2018. As summarized by The Boston Globe, “The extraordinary move, made in informal sessions with just a half-dozen legislators present, would unravel a significant part of the legalization measure passed by 1.8 million voters just last month.” Governor Charlie Baker signed the bill into law just two days later.

But this was only the beginning.

Now, Senator Jason M. Lewis is proposing bills that would reduce the amount of marijuana that an individual can possess, restrict the number of plants that a person can grow, and ban various forms of THC infused products including edibles.

The arrogance and hubris lawmakers are showing toward voters is shocking, and is typified by the comments of Senate President Stanley C. Rosenberg who, only hours after the vote, pronounced: “I believe that when voters vote on most ballot questions, they are voting in principle. They are not voting on the fine detail that is contained within the proposal.”

It’s time for you to send another clear message to your lawmakers: Abide by voters’ decision or suffer the consequences.

MA Resident? Click here to email your representatives to urge them to support this effort.

Nebraska

State Senator Anna Wishart has introduced comprehensive medical marijuana legislation, LB622.

Senator Wishart’s bill is similar to legislation that was introduced in 2016 and narrowly defeated. LB622 will allow patients with conditions such as Crohn’s disease, epilepsy, opioid addictions and some types of cancer to obtain marijuana. Additionally it would permit patients to grow up to 12 plants and/or possess up to six ounces of cannabis for therapeutic purposes. Last year’s bill was narrowly defeated by lawmakers.

Twenty-nine states and the District of Columbia have enacted statewide provisions allowing patients access to cannabis therapy. Nebraska patients deserve these same protections.

NE Resident? Click here to email your representatives to urge them to support this effort.

New Hampshire

After nearly a decade of frustration, 2017 may finally be the year that New Hampshire voters successfully see marijuana possession decriminalized.

HB640, sponsored by 6 Republicans and 6 Democrats, will amend criminal penalties for marijuana possession is pending in the House, where lawmakers have overwhelmingly supported such efforts for eight years in a row. However, legislators this year are hopeful that, for the first time, they also have sufficient votes to also clear the Senate.

NH Resident? Click here to email your representatives to urge them to support this effort.

Additionally, Multiple bills are pending before lawmakers to expand the pool of patients eligible to qualify for medical marijuana therapy.

In particular, these measures would permit patients with conditions like chronic pain and post-traumatic stress to obtain legal access to marijuana.

Most recently, an exhaustive report released by the National Academies of Sciences determined that there is “conclusive” evidence that cannabis is “effective for the treatment of chronic pain.” Authors concluded, “In adults with chronic pain, patients who were treated with cannabis or cannabinoids (constituents found organically in the marijuana plant) are more likely to experience a clinically significant reduction of pain symptoms.”

NH Resident? Click here to email your representatives to urge them to support this effort.

New York

Senator Liz Krueger (D) has introduced the Marijuana Regulation and Taxation Act in the New York General Legislature.

The act legalizes possession and cultivation, and would establish a market for legal marijuana for adults 21 and older.

NY Resident? Click here to email your representatives to urge them to support this effort.

North Dakota

Legislation is pending, HB 1340, in the statehouse to decriminalize the possession of marijuana and marijuana-related paraphernalia.

Under existing law, marijuana possession of one ounce or less is punishable by up to 30 days in jail and a $1,500 fine, while the possession of greater amounts are classified as a felony offense punishable by up to five years in prison. Possessing marijuana-related paraphernalia is punishable by up to one year in jail and a $3,000 fine.

ND Resident? Click here to email your representatives to urge them to support this effort.

Virginia

UPDATE: SB1091 has passed the full Senate by a vote of 38-2 and HB 2051 has passed it’s first committee vote in the House of Delegates.

State Senators Adam Ebbin (D), Bill Stanley (R) and Delegate Les Adams (R) have introduced SB 1091 and HB 2051 respectively, legislation that would remove the mandatory driver’s license suspension currently imposed for those with a marijuana possession conviction.

Under current law, any drug conviction, regardless of whether or not a motor vehicle was involved, results in an automatic suspension of the individual’s driving privileges for 6 months.

VA Resident? Click here to email your representatives to urge them to support this effort.

Additionally, SB 1298 has cleared the Senate Courts of Justice Committee on a 9-4 vote as it seeks to establish affirmative defense for possession of cannabidiol if an individual has written certification that they require the substance due to an approved medical condition.

Affirmative defense establishes a basic set of facts surrounding cannabidiol possession cases. If someone with a qualifying medical condition is caught possessing marijuana, an affirmative defense for the individual would likely result in a more lenient punishment.

VA Resident? Click here to email your representatives to urge them to support this effort.

Washington

UPDATE: HB 1212 has passed committee, making it the first piece of legislation for home cultivation in Washington state history.

Legislation is pending before the House, HB 1094 and HB 1212, to prohibit employers from discriminating against patients who legally consume marijuana during non-work hours.

The bill amends existing law so that: “An employer  may not refuse to hire a qualifying patient, discharge or bar a qualifying patient from employment, or discriminate against a qualifying patient in compensation or in other terms and conditions of employment because of the qualifying patient’s: (i) Status as a qualifying patient; or (ii) Positive drug test for marijuana components or metabolites.”

Changes in the legal status of marijuana has not been associated with any adverse changes in workplace safety. In fact, a pair of studies from 2016 find that legalization is associated with greater workforce participation and with fewer workplace absences. Most recently, the National Academies of Sciences just-released marijuana and health report found “insufficient evidence” to support an association between cannabis use and occupational accidents or injuries.

WA Resident? Click here to email your representatives to urge them to support this effort.

 

 

NORML Responds To National Academy of Sciences’ Marijuana Report

for_painThe National Academy of Sciences, Engineering, and Medicine released a comprehensive report today acknowledging that “conclusive or substantial evidence” exists for cannabis’ efficacy in patients suffering from chronic pain, and sharply criticized longstanding federal regulatory barriers to marijuana research – in particular “the classification of cannabis as a Schedule I substance” under federal law.

Authors of the report also addressed various aspects of marijuana’s effect on health and safety, acknowledging that the substance may pose certain potential risks for adolescents, pregnant women, and for those who may be driving shortly after ingesting cannabis. In each of these cases, these risks may be mitigated via marijuana regulation and the imposition of age restrictions in the marketplace.

Commenting on the report, NORML Deputy Director Paul Armentano said:

“The National Academy of Science’s conclusions that marijuana possesses established therapeutic utility for certain patients and that it possesses an acceptable safety profile when compared to those of other medications or recreational intoxicants are not surprising. This evidence has been available for some time, yet for decades marijuana policy in this country has largely been driven by rhetoric and emotion, not science and evidence.

“A search on PubMed, the repository for all peer-reviewed scientific papers, using the term ‘marijuana’ yields over 24,000 scientific papers referencing the plant or its biologically active constituents — a far greater body of literature than exists for commonly consumed conventional drugs like Tylenol, ibuprofen, or hydrocodone. Further, unlike modern pharmaceuticals, cannabis possesses an extensive history of human use dating back thousands of years, thus providing society with ample empirical evidence as to its relative safety and efficacy.

“Today, 29 states and Washington, DC permit physicians to recommend marijuana therapy. Some of these state-sanctioned programs have now been in place for nearly two decades. Eight states also permit the regulated use and sale of cannabis by adults. At a minimum, we know enough about cannabis, as well as the failures of cannabis prohibition, to regulate its consumption by adults, end its longstanding criminalization, and to remove it from its Schedule I prohibitive under federal law.”

The report marks the first time since 1999 that the National Academy of Sciences has addressed issues surrounding marijuana and health. Authors reviewed over 10,000 scientific abstracts in their preparation of the new report.

You can read the full report here.

Canadian Government’s Legal Marijuana Task Force Releases Recommendations

legalizationThis morning in Ottawa, a government task force assigned to study legalizing and regulating the adult use of marijuana in Canada released their recommendations. The task force recommended that sales should be restricted to those over the age of 18 with a personal possession limit of 30 grams. Their recommended model of legalization would put heavy restrictions on most types of cannabis advertising and tax the product based on THC content. The task force suggested that both storefronts and delivery services would be allowed as well as the home cultivation of up to four plants. They also believe that all of Canada’s current laws regarding medical marijuana remain in place as they are currently with no change.

“The prohibitory regime exists does not work and has not met the basic principles of public health and safety that have to be at the core of this public policy,” stated Anne McLellan, former minister of justice and chair of the task force.

The group’s nine members had discussions with scientific experts across Canada and received the opinions of over 28,000 citizens via online consultations before making their recommendations. They also made visits to states in the US that have already legalized marijuana for adult consumption.

While the task force’s recommendations are non-binding, they announced during the press conference that the Canadian government will present legislation in the spring of 2017 modeled after this report. The implementation date of that legislation is still unclear.

With Canada blazing a new and smarter path forward on marijuana policy, the pressure will only continue to build on the United States government to reform our federal marijuana laws.

You can read the full report HERE.

Florida Voters Approve Expansive Medical Marijuana Law

According to the Associated Press, voters in Florida will approve Amendment 2, an expansive medical marijuana law. The AP has the measure leading by a vote of 71 percent to 29 percent, and has called the race. The Amendment required over 60 percent of the vote to become law.

“The overwhelming majority of Floridians, like voters nationwide, believe that patients ought to have the legal option to choose marijuana therapy as an alternative to conventional, and often dangerous, pharmaceuticals,” said NORML Deputy Director Paul Armentano. “With this historic vote, we can expect to see similar programs acknowledging the safety and efficacy of medical cannabis begin to take hold in the southeastern region of the United States.”

Florida Medical Marijuana

Amendment 2 amends the Florida state constitution so that qualified patients who possess a physician’s recommendation may legally possess and obtain medical cannabis provided by state licensed dispensaries. Under the law, a “debilitating medical condition” for which marijuana may be recommended includes is defined as “cancer, epilepsy, glaucoma, positive status for human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), post-traumatic stress disorder (PTSD), amyotrophic lateral sclerosis (ALS), Crohn’s disease, Parkinson’s disease, multiple sclerosis, or other debilitating medical conditions of the same kind or class as or comparable to those enumerated, and for which a physician believes that the medical use of marijuana would likely outweigh the potential health risks for a patient.” The home cultivation of cannabis is not permitted under the law.

Existing Florida law restricted limited qualifying patients only to high CBD strains of cannabis, unless they were terminally ill.

Department of Health regulators must begin issuing patient identification cards within nine months of the new law’s enactment. You can read the full text of Amendment 2 here.

“With broad support across all demographics, voters in Florida approved Amendment 2 by a landslide,” said Erik Altieri, NORML’s new Executive Director. “These results are a victory, not just for common sense public policy, but for patients all across the state who will now have access to a safe, effective treatment for a number of debilitating ailments.”

Report: Tax Revenue From Retail Marijuana Sales Exceeds Expectations

legalization_pollTax revenue collection from retail marijuana sales in Colorado, Oregon, and Washington is exceeding initial projections, according to a new report published by the Drug Policy Alliance.

Marijuana-related tax revenue in Colorado totaled $129 million over the 12-month period ending May 31, 2016 – well exceeding initial estimates of $70 million per year, the report found. In Washington, tax revenue totaled $220 million for the 12-month period ending June 30, 2016. Regulators had initially projected that retail sales would bring in $162 million in new annual tax revenue. In Oregon, marijuana-related tax revenues are yielding about $4 million per month – about twice what regulators initially predicted. (Alaska has yet to begin collecting tax revenue from cannabis businesses.)

The report also finds that adult use marijuana legalization has not been associated with any increases in youth use of the substance, nor has it had an adverse impact on traffic safety. “In Colorado and Washington the post-legalization traffic fatality rate has remained statistically consistent with pre-legalization levels, is lower in each state than it was a decade prior, and is lower than the national rate,” it determined. A separate report published by the CATO Institute recently provided similar findings.

In addition, the new reports finds that marijuana-related arrest totals have fallen significantly in jurisdictions post-legalization. According to the DPA’s report, the total number for all annual marijuana-related arrests decreased by 59 percent in Alaska, by 46 percent in Colorado, by 85 percent in the District of Columbia, and by 50 percent in Oregon. In Washington, the number of low-level marijuana court filings fell by 98 percent.

To read the full report, please click here.

DEA Reaffirms ‘Flat Earth’ Position With Regard To Scheduling Marijuana

imgresThe United States Drug Enforcement Administration has rejected a pair of administrative petitions that sought to initiate rulemaking proceedings to reschedule marijuana under federal law.

Although the DEA’s ruling continues to classify marijuana in the same category as heroin, the agency also announced in a separate decision that it is adopting policy changes designed to expand the production of research-grade cannabis for FDA-approved clinical studies.

Presently, any clinical trial involving cannabis must access source material cultivated at the University of Mississippi — a prohibition that is not in place for other controlled substances. Today, the agency announced for the first time that it will be seeking applications from multiple parties, including potentially from private entities, to produce marijuana for FDA-approved research protocols as well as for “commercial product development.” This change was initially recommended by the DEA’s own administrative law judge in 2007, but her decision was ultimately rejected by the agency in 2011.

Below is a statement from NORML Deputy Director Paul Armentano regarding the DEA’s decisions:

For far too long, federal regulations have made clinical investigations involving cannabis needlessly onerous and have placed unnecessary and arbitrary restrictions on marijuana that do not exist for other controlled substances, including some other schedule I controlled substances.

While this announcement is a significant step toward better facilitating and expanding clinical investigations into cannabis’ therapeutic efficacy, ample scientific evidence already exists to remove cannabis from its schedule I classification and to acknowledge its relative safety compared to other scheduled substances, like opioids, and unscheduled substances, such as alcohol. Ultimately, the federal government ought to remove cannabis from the Controlled Substances Act altogether in a manner similar to alcohol and tobacco, thus providing states the power to establish their own marijuana regulatory policies free from federal intrusion.

Since the DEA has failed to take such action, then it is incumbent that members of Congress act swiftly to amend cannabis’ criminal status in a way that comports with both public and scientific opinion. Failure to do so continues the federal government’s ‘Flat Earth’ position; it willfully ignores the well-established therapeutic properties associated with the plant and it ignores the laws in 26 states recognizing marijuana’s therapeutic efficacy.

Under the U.S. Controlled Substances Act of 1970, the cannabis plant and its organic cannabinoids are classified as Schedule I prohibited substances — the most restrictive category available under the law. By definition, substances in this category must meet three specific inclusion criteria:

The substance must possess “a high potential for abuse”; it must have “no currently accepted medical use” in the United States; and, the substance must lack “accepted safety for use … under medical supervision.”

Substances that do not meet these criteria must, by law, be categorized in less restrictive federal schedules (Schedules II through V) and are legally regulated accordingly. Alcohol and tobacco, two substances widely acknowledged to possess far greater dangers to health than does cannabis, are not classified under the Controlled Substances Act.

A recent review of FDA-approved clinical studies evaluating the safety and efficacy of herbal cannabis concluded: “Based on evidence currently available the Schedule I classification is not tenable; it is not accurate that cannabis has no medical value, or that Information on safety is lacking.”

Added Armentano: “The DEA’s decision is strictly a political one. There is nothing scientific about willful ignorance.”

The DEA has previously rejected several other rescheduling petitions, including a 2002 petition filed by a coalition of marijuana law reform and health advocacy organizations, and a 1972 petition filed by NORML. The petitions that triggered this latest DEA action were filed in 2009 by a nurse practitioner and 011 by then-Govs. Christine Gregoire of Washington and Lincoln Chafee of Rhode Island.

Login | Register

Copyright Top Nug © All Rights Reserved · Top Nug Theme by Ame

PIXSELL8 Pixel Count Remaining